ProCE Banner Activity

Adjuvant Therapy for Patients With HR+/HER2- EBC at High Risk of Recurrence

Slideset Download

Get up to date on how to optimally integrate CDK4/6 inhibitors into adjuvant therapy for patients with HR-positive, HER2-negative early breast cancer, from individualizing treatment selection to managing adverse events.

Released: June 16, 2021

Share

Faculty

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Aadi Bio, Artios, Arvinas, AstraZeneca, Bayer, BioNTech, Blueprint Medicines, Bristol Myers Squibb, Circle Pharma, Cullinan Oncology, CytomX, Daiichi Sankyo, eFFECTOR, Eisai, Genentech/Roche, Gilead, Hengrui USA, Incyte Corp, Jazz, Lilly, Menarini/Stemline, Merck, Natera, Novartis, Pfizer/SeaGen, Reveal Genomics, Sanofi, Sumitovant Biopharma, SystImmune, Tango, Umoja Biopharma, Zentalis, Zymeworks; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Exelixis, Genentech/Roche, Gilead, Lilly, Menarini/Stemline, Merck, NanoString Technologies, Merck, Novartis, OncoPep, Pfizer, Seattle Genetics; other (travel support): BioNTech, Gilead, Jazz, Lilly, Pfizer, Sanofi.